Skip to main content

N Katakami

First name:
N
Last name:
Katakami
Irie, Y. ., Katakami, N. ., Mita, T. ., Takahara, M. ., Matsuoka, T. ., Gosho, M. ., … Atherosclerosis, C. S. of P. E. of A. on D. (2018). Evaluation of the Effect of Alogliptin on Tissue Characteristics of the Carotid Wall: Subanalysis of the SPEAD-A Trial. Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders. https://doi.org/10.1007/s13300-018-0367-7 (Original work published 2018)
Masago, K. ., Fujita, S. ., Hata, A. ., Okuda, C. ., Yoshizumi, Y. ., Kaji, R. ., … Yatabe, Y. . (2018). Validation of the digital PCR system in tyrosine kinase inhibitor-resistant EGFR mutant non-small-cell lung cancer. Pathology International. https://doi.org/10.1111/pin.12630 (Original work published 2018)
Ogawa, K. ., Ito, J. ., Fujimoto, D. ., Morita, M. ., Yoshizumi, Y. ., Ariyoshi, K. ., … Katakami, N. . (2018). Exacerbation of autoimmune hemolytic anemia induced by the first dose of programmed death-1 inhibitor pembrolizumab: a case report. Investigational New Drugs. https://doi.org/10.1007/s10637-018-0561-5 (Original work published 2018)
Kiura, K. ., Yoh, K. ., Katakami, N. ., Nogami, N. ., Kasahara, K. ., Takahashi, T. ., … Uchida, H. . (2018). Osimertinib in patients with EGFR T790M advanced non-small cell lung cancer selected using cytology samples. Cancer Science. https://doi.org/10.1111/cas.13511 (Original work published 2018)
Hata, A. ., Katakami, N. ., Nanjo, S. ., Okuda, C. ., Kaji, R. ., Masago, K. ., … Hirata, Y. . (2017). Programmed death-ligand 1 expression according to epidermal growth factor receptor mutation status in pretreated non-small cell lung cancer. Oncotarget, 8(69), 113807-113816. https://doi.org/10.18632/oncotarget.22837 (Original work published 2017)